Yu Sicong, Chen Keda, Fang Lei, Mao Haiyan, Lou Xiuyu, Li Chaonan, Zhang Yanjun
School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Vaccines (Basel). 2021 Jun 2;9(6):588. doi: 10.3390/vaccines9060588.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) pose a great threat to humanity. Every pandemic involving these coronaviruses has seriously affected human health and economic development. Currently, there are no approved therapeutic drugs against their infections. Therefore, the development of vaccines is particularly important to combat these coronaviruses. In this review, we summarized and analyzed the progress of vaccines against SARS-CoV, MERS-CoV, and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, nucleic acid vaccines, and viral vector vaccines. In addition, we compared the levels of neutralizing antibodies in the serum of patients with these three kinds of coronaviruses at different stages, and their ability and effects against SARS-CoV-2, MERS-CoV, and SARS-CoV. This review provides useful information for vaccine evaluation and analysis.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒（SARS-CoV）对人类构成了巨大威胁。每一次涉及这些冠状病毒的大流行都严重影响了人类健康和经济发展。目前，尚无针对其感染的获批治疗药物。因此，开发疫苗对于对抗这些冠状病毒尤为重要。在本综述中，我们总结并分析了针对SARS-CoV、MERS-CoV和SARS-CoV-2的疫苗研发进展，包括灭活疫苗、减毒活疫苗、亚单位疫苗、核酸疫苗和病毒载体疫苗。此外，我们比较了这三种冠状病毒患者在不同阶段血清中的中和抗体水平，以及它们对SARS-CoV-2、MERS-CoV和SARS-CoV的作用能力和效果。本综述为疫苗评估和分析提供了有用信息。
Zotero 插件